Compare GSK plc (GSK) vs Symbotic Inc (SYM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Symbotic Inc — how do they compare? GSK plc trades at $46.82 (market cap $91.88B), while Symbotic Inc trades at $42.67 (market cap $5.46B). The key difference: GSK plc is far larger — about 16.8× Symbotic Inc's market cap, and GSK plc pays a 3.9% dividend while Symbotic Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Symbotic Inc for 23 Days on average.
| GSK | SYM | |
|---|---|---|
Market Cap | $91.88B | $5.46B |
Volume | 7,730,529 | 1,965,805 |
Sector | Health | Industrials |
52-Week High | $61.18 | $87.30 |
52-Week Low | $43.24 | $38.22 |
Typical Hold Time | 93 Days | 23 Days |
Enterprise Value | $111.88B | $3.72B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.02, up 0.9% today, with a bearish technical signal but strong fundamentals. The company reported revenue of $32.67B in 2025 with a net income margin of 14.52% and has beaten EPS estimates for three consecutive quarters. Recent news highlights strategic oncology investments and a $750M deal for a cancer therapy, signaling growth initiatives.
The outlook is mixed: solid profitability and a reasonable P/E of 15.1 support value, but technical indicators show bearish pressure near key support at $46. Risks include patent expirations and competitive pressures, while analyst sentiment is cautious with 31% buy ratings. Upside depends on pipeline execution and cost savings.
SYM trades at $43.31, down 1.9% on the day, with a bullish technical signal from moving averages but mixed earnings performance. The company reported negative net income of -$16.94M for 2025 despite $2.25B revenue, though 2026 projections show improvement to $8M net profit. Analysts maintain a buy consensus with a $60.33 price target, representing 39% upside potential from current levels.
SYM presents growth potential with a massive $22.5B backlog and expanding robotics/AI market, but faces significant customer concentration risk (85% revenue from Walmart) and recent earnings misses. The stock appears undervalued with a P/E of 1.05, though high EV/EBITDA of 74.05 suggests premium valuation relative to current earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Symbotic Inc
Symbotic is an automation technology leader that provides an end-to-end, A.I.-powered robotic platform for large-scale warehouse operations. By utilizing untethered, high-speed autonomous bots and sophisticated vision systems, Symbotic transforms traditional distribution centers into high-density strategic assets. The company serves the world’s largest retailers and wholesalers—most notably Walmart—while expanding into 'Warehouse-as-a-Service' through its GreenBox joint venture to democratize advanced automation for smaller enterprises.
Read more on SYM →
